Logo image
Back
Methimazole Associated Neutropenia in a Preterm Neonate Treated for Hyperthyroidism
Journal article   Open access   Peer reviewed

Methimazole Associated Neutropenia in a Preterm Neonate Treated for Hyperthyroidism

Dimitrios Angelis, Rita Ann Kubicky and Alan B. Zubrow
Case reports in endocrinology, v 2015, 680191
01 Jan 2015
DOI: https://doi.org/10.1155/2015/680191
PMID: 25810932
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1155/2015/680191View
Published, Version of Record (VoR)CC BY V4.0,  Open

Abstract

Endocrinology & Metabolism Life Sciences & Biomedicine Science & Technology
Maternal Graves' disease is relatively uncommon with an estimated incidence of 0.4%-1% of all pregnancies, but only 1-5% of newborns delivered to mothers with Graves' disease develop overt clinical signs and symptoms of hyperthyroidism. Here, we describe a case of a 1380-gram female neonate who was born at 30-week gestation to a mother with Graves' disease. Our patient presented with hyperthyroidism followed by transient hypothyroidism requiring treatment with levothyroxine. While hyperthyroid, she was treated with methimazole, iodine, and a beta-blocker. 20 days after the initiation of methimazole, she developed neutropenia. The neutrophil counts started to improve immediately after the initiation of the weaning of methimazole. To the best of our knowledge, this is the first case reported in the literature of methimazole induced neutropenia in a preterm infant being treated for neonatal Graves' disease.

Metrics

32 Record Views
4 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Endocrinology & Metabolism
Logo image